Indication intelligence, analysis and sector perception

RegMedInvestors (RMi) Finance note: Prime Medicine (PRME) closes 43.7 M share offering at $3.30

August 1, 2025 4:52pm

PRME closed Friday at $4.04 ...

And the full exercise of the 5.7 K underwriters’ option at $3.30 per share.

The gross proceeds before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 M.

TD Cowen and BMO Capital Markets are acting as joint book-running managers for the proposed offering.

A thirst was satisfied ... luck was glamour model and not a fatty ...

The underwriters will not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation.

PRME has also granted the underwriters a 30-day option to purchase up to an additional 5,700,000 shares of its common stock.

The Bottom Line: pieces of the stats puzzle – desperate straits ... as I had questioned with the WHY ...

Revenue: $3.85M
Past Q Cash: $144.26 M
Debt: $121.15 M
52-week High: 5.94 on 07/31/24
52-week Low: 1.11 on 05/22/25
52-week change: -31.73%
Market Cap: 527.224M
50-day moving average: 2.6133
200-day moving average: 2.6688
10 Day Average Volume: 4.79M
Float: 61.32 shares
Shares short: 21.66 M
Short % of Float (7/15/2025): 33.51%
Shares Outstanding: 134.5 M
% held by insiders: 23.65%
% held by institutions:55.46%
Beta: 2.32
YTD % Change: -34.25%

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.